

Day 1	Policy and Epidemiology				
07.00	Registration				
08.30 - 12.30	Opening Ceremony and Session A: How do we work together to achieve HCV elimination among PWID? Room: Sala I + II Chairs: TBC				
08.30 - 08.40	Welcome to the Conference Rui Tato Marinho, Hospital Santa Maria; Medical School of Lisbon; Portuguese Society of Gastroenterology, Portugal; Jeffrey Lazarus, ISGlobal; Hospital Clínic; University of Barcelona, Spain; Ricardo Baptista Leite, Ricardo Baptista Leite, Member of Parliament, Portuguese National Parliament, Portugal; Luís Mendão				
08.40 - 08.50	TBC				
08.50 - 09.00	Community Opening and Report from Community Summit Eberhard Schatz, Correlation Network, Amsterdam; Magda Ferreira, GAT Portugal				
09.00 - 09.10	Policy Opening and Report from Policy Day Ricardo Baptista Leite, Member of Parliament, Portuguese National Parliament, Portugal				
09.10 - 09.15	Opening from European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Alexis Goosdeel, European Monitoring Centre for Drugs and Drug Addiction, (EMCDDA), Portugal				
09.15 - 09.35	Successes and challenges of drug policy in Portugal: Decriminalization is not enough João Goulão, General-Directorate for Intervention on Addictive Behaviours and Dependencies (SICAD), Portugal				
09.35 - 09.55	What will it take to achieve the HCV elimination goals among people who inject drugs? Annette Verster, World Health Organization, Switzerland				
09.55 - 10.05	Questions & Discussion				
10.05 - 10.35	Coffee Break and Poster Viewing				
10.35 - 11.20	Humanising efforts to reach people who inject drugs: Decriminalisation, Rights, and Health Chair: Judy Chang, International Network of People who Use Drugs (INPUD), United Kingdom Panellists: Alex Stevens, University of Kent, United Kingdom; Rui Miguel Coimbra Morais, Consumers Associated Survive Organised (CASO), Portugal; James Dunne, Vienna; Jude Byrne, Australian Injecting & Illicit Drug Users League (AIVL), Australia				
11.20 - 12.00	Panel Disussion: How can we better integrate health policies to enhance drug user health and HCV care among people who use drugs? Moderated by Ricardo Baptista Leite, Member of Parliament, Portuguese National Parliament, Portugal				
12.00 - 12.15	Opiate Agonist Therapy And Prevention Of HCV Transmission Among People Who Inject Drugs: The Importance Of Clinically-Indicated And Patient-Perceived Dosage Adequacy Andreea Adelina Artenie, Université De Montréal, Canada				
12.15 - 12.30	Rural Risk Environment For Hepatitis C Among Young Adults Who Use Opioids In Appalachian Kentucky David Cloud, Emory University, Rollins School Of Public Health, United States				
12.30 - 14.00	Lunch and Poster Viewing				
12.45 - 13.45	Industry Sponsored Lunch Symposium				
14.00 - 15.15	Session B: Oral Abstracts Room: TBC Chairs: TBC	14.00 - 15.15	Session C: Oral Abstracts Room: TBC Chairs: TBC	14.00 - 15.15	Session D: Oral Abstracts Room: TBC Chairs: TBC
14.00 - 14.15	Estimating The Number Of People Who Inject Drugs In Athens, Greece: Implications For The Burden Of Hepatitis C Infection And The Coverage Of Harm Reduction Programs Sotirios Roussos, University Of Athens, Greece	14.00 - 14.15	Client And Staff Perspectives On Point-Of-Care Hepatitis C Testing For People Attending Needle Syringe Programs Ned Latham, Burnet Institute, Australia	14.00 - 14.15	Community Outreach Events – Engaging The Disengaged Arshia Alimohammadi, Vancouver Infectious Diseases Centre, Canada
14.15 - 14.30	Sexualised Drug Use And Co-Occurring High Risk Behaviours Among Gay And Brendan Harney, Alfred Health & Burnet Institute, Australia	14.15 - 14.30	Factors Associated With HCV Testing Among People Who Inject Drugs In An Urban Setting In Vietnam Giang Le, Hanoi Medical University, Vietnam	14.15 - 14.30	The Kombi Clinic Driving Out Hep C In South East Queensland Disenfranchised Communities Joss O'Loan, Kombi Clinic, Australia
14.30 - 14.45	Sex, Drugs And HCV: The Role Of Sex And Sex Work In Hepatitis C Virus Brendan Jacka, CHUM Research Centre, Canada	14.30 - 14.45	Hepcatt (Hepatitis C Assessment To Treatment Trial) In Primary Care: A Cluster RCT Of Whether A Matthew Hickman, Population Health Sciences, Bristol Medical School, United Kingdom	14.30 - 14.45	Hepatitis C Screening and Linkage to Care at Four New York City Syringe Exchange Programs Diana Diaz Munoz, NYC Department Of Health And Mental Hygiene, United States
14.45 - 14.50	Exposing The Need For Viral Hepatitis C Services For People Who Inject Drugs In South Africa: Findings From A Three-City Cross Sectional Survey Andrew Scheibe, TB HIV Care, South Africa	14.45 - 14.50	Linking Hepatitis C Infection People Who Inject Drugs To Treatment And Care, South Africa Angela McBride, Out Well-being, Harmless Project, South Africa	14.45 - 14.50	An Onsite Primary Care Based Approach Allows Rapid Reduction Of Hepatitis C Prevalence In Prison. A Case Study From Canberra, Australia Michael Levy, ACT Justice Health Service, Australia
14.50 - 14.55	Increase In HCV Prevalence Among People Who Inject Drugs In Ukraine Iana Sazonova, Icf 'alliance For Public Health', Ukraine	14.50 - 14.55	Straight To The Point – Lessons From The Rapid-EC Study: A Point-Of-Care Hepatitis C Testing Pilot In Alisa Pedrana, Burnet Institute, Australia	14.50 - 14.55	The Road To Hepatitis C Elimination: A Change In Care Pathway Increases Access To Hepatitis C Brian Stephens, NHS Tayside, United Kingdom
14.55 - 15.00	Increased Risk Of Hepatitis-C Virus And Skin And Soft Tissue Infection Among Andrew McAuley, Glasgow Caledonian University, United Kingdom	14.55 - 15.00	The National Stigma Indicator Project: Key Findings and Lessons Regarding People Living With HCV Carla Treloar, University of New South Wales, Australia	14.55 - 15.00	Implementation Of Routine HIV/HCV Screening And Linkage To Care In The Idea Exchange; Miami, FL Tyler Bartholomew, University of Miami, United States
15.00 - 15.05	Correlations Between Injecting Frequency And Housing Stability Trajectories Emmanuel Fortier, CHUM Research Centre, Canada	15.00 - 15.05	Late Breaker Abstract Presenter, Institution, Country	15.00 - 15.05	A Community-Based Model Of Peer-Led Anonymous Rapid Hepatitis C (HCV) Testing For People Who Arnaud Nicolas Patrick Manbode, P.I.L.S, Mauritius
15.05 - 15.10	Housing Stability And Hepatitis C Infection For Young Adults Who Inject Drugs: Meghan Morris, University Of California, San Francisco, United States	15.05 - 15.10	Late Breaker Abstract Presenter, Institution, Country	15.05 - 15.10	A Responsive Model Of Care Utilizing A Collaborative Nurse Practitioner And Peer Based Model Of Care Leanne Myers, Peer Based Harm Reduction WA, Australia
15.10 - 15.15	Attenuated Protective Effect Of Opioid Agonist Therapy On Hepatitis C Incidence Among Females Kimberly Page, University Of New Mexico, United States	15.10 - 15.15	Late Breaker Abstract Presenter, Institution, Country	15.10 - 15.15	Health Prevention Delegate : visiting general practitioners and pharmacists in the Pyrénées Atlantiques Area (France) Cecilia Maitre, Resapsad, France
15.15 - 16.15	Coffee Break & Poster Tour				
16.15 - 17.45	Session E: Epidemiology and Public Health Room: TBC Chairs: TBC	16.15 - 17.30	Session F: Integration of HCV, other co-infections and harm reduction services Room: TBC Chairs: Jeffrey Lazarus and TBD		
16.15 - 16.35	Epidemiology of HCV infection among people who inject drugs: Where do we really need to focus our efforts to eliminate HCV globally? Matthew Hickman, University of Bristol, United Kingdom	16.15 - 16.20	What does the EU mean by "integrated" infectious disease programmes and what policy developments have there been to further this agenda? Jean Luc Sion, DG SANTE, Portugal		
		16.20 - 16.30	How do EU agencies take an integrated approach to hepatitis C control Dagmar Hedrich, European Monitoring Centre for Drugs and Drug Addiction, (EMCDDA), Portugal		
16.35 - 16.55	Will HCV reinfection compromise our elimination efforts? Gregory Dore, Kirby Institute, University of New South Wales, Australia	16.30 - 16.40	Best practice model from a Luxembourg prison Patrick Hoffman, HA-REACT, Luxembourg		
		16.40 - 16.55	Transitioning specialist HCV services into the community Jack Lambert, Hep-CARE, United Kingdom; Alistair Story, E-DETECT, United Kingdom		
16.55 - 17.15	Women who inject drugs Alena Asaeva, Eurasian Network of People who use Drugs (ENPUD), Russia	16.55 - 17.30	What does integration of services for PWID mean in terms of testing and providing treatment? How does the health Panellists: Jeffrey Lazarus, HA-REACT, Spain; Dorthe Raben, INTEGRATE, Denmark; Jack Lambert, Hep-Care, United		
17.15 - 17.45	Questions & Discussion				
17.45	End of Conference Day 1				
17.45 - 19.00	Welcome Reception & Poster Viewing				

Day 2	HCV diagnosis, linkage to care and treatment				
07.30	Registration				
08.00 - 08.45	Industry Sponsored Breakfast Symposium Room: Sala I + II				
09.00 - 10.45	Session G: Enhancing the HCV care cascade Room: Sala I + II Chairs: TBC				
09:00 - 09:20	Point-of-care testing and diagnostics for HCV infection: Have we reached a single-visit diagnosis? Karine Lacombe, Sorbonne-Universités, Inserm - APHP, France				
09:20 - 09:40	Strategies to foster task-shifting and broaden models of HCV prevention and care John Dillon, University of Dundee, United Kingdom				
09:40 - 10:00	Strategies to facilitate linkage to care for PWID in low and middle income countries Shruti Mehta, John Hopkins Bloomberg School of Public Health, United States				
10:00 - 10:15	Questions & Discussion				
10:15 - 10:30	Cost-Effectiveness Analysis Of Testing Strategies For Diagnosing Hepatitis C Virus Infection In PWIDS In Resource-Constrained Countries Léa Duchesne, Inserm, France				
10:30 - 10:45	Direct-Acting Antiviral Therapy For Hepatitis C Virus Infection Among People Who Inject Drugs: A Systematic Review And Meta-Analysis Behzad Hajarizadeh, University Of New South Wales, Australia				
10.45 - 11.15	Coffee Break and Poster Viewing				
11.15 - 12.15	Session H: Workshops				
11.15 - 12.15	Is it Cirrhosis? Is it Cancer? A Practical Guide Rui Tato Marinho, Hospital Santa Maria; Medical School of Lisbon; Portuguese Society of Gastroenterology, Portugal	11.15 - 12.15	Meaningful Patient And Public Involvement In HCV Research: A Focus On Peer Researchers Rebekah Moore, Scottish Drugs Forum, United Kingdom		
11.15 - 12.15	Session I: Oral Abstracts Room: TBC Chairs: TBC	11.15 - 12.15	Session J: Oral Abstracts Room: TBC Chairs: TBC		
11.15 - 11.30	The Cost-Effectiveness Of Undertaking HCV Treatment In Needle And Syringe Programmes In Tayside, Scotland Zoe Ward, University Of Bristol, United Kingdom	11.15 - 11.30	Do National HCV Policies In The EU Address Treatment And Care For People Who Inject Drugs? Stine Neilsen, Freelance, Spain		
11.30 - 11.45	Late Breaker Abstract Presenter, Institution, Country	11.30 - 11.45	Barriers And Facilitators Of Hepatitis C (HCV) Treatment Initiation Among People Who Inject Drugs In The Era Of New Direct Acting Antivirals Iuliia Makarenko, McGill University, Canada		
11.45 - 12.00	Late Breaker Abstract Presenter, Institution, Country	11.45 - 12.00	W3 Framework: Understanding The Role And Quality Of Peer Led Programs By People Who Inject Drugs In A National Hepatitis C Response Graham Brown, Australian Research Centre In Sex, Health And Society, La Trobe University, Australia		
12.00 - 12.05	Modelling The Impact Of Prevention And Treatment Interventions On Hiv And Hepatitis C Virus Transmission Among People Who Inject Drugs In Nairobi Jack Stone, University Of Bristol, United Kingdom	12.00 - 12.05	Knowledge Around Direct Acting Antiviral Therapies And Willingness To Undergo HCV Treatment Among Rural Appalachian Opioid Users Jennifer Havens, University Of Kentucky College Of Medicine, United States		
12.05 - 12.10	The Results Of HIV And Hcv Prevention Program Among PWID In Ukraine Tetiana Mykhalchuk, Peer Based Harm Reduction WA, Australia	12.05 - 12.10	Attitude Of Staff Regarding Integrated Hepatitis C Treatment At Eight Harm Reduction Centers In Georgia Lasha Gulbani, Health Research Union, Georgia		
12.10 - 12.15	Cost-Effectiveness Of Scaling-Up Syringe Service Provision Among People Who Inject Drugs In Perry County, Kentucky Hannah Fraser, University Of Bristol, United Kingdom	12.10 - 12.15	Integrating Hepatitis C Care For At-Risk Groups: Findings From A Multi-Centre Observational Study In Primary And Community Care Davina Swan, University College Dublin, Ireland		
12.15 - 13.45	Lunch and Poster Viewing				
12.30 - 13.30	Industry Sponsored Lunch Symposium				
13.45 - 15.00	Session K: Oral Abstracts Room: TBC Chairs: TBC	13.45 - 15.00	Session L: Oral Abstracts Room: TBC Chairs: TBC	13.45 - 15.00	Session M: Oral Abstracts Room: TBC Chairs: TBC
13.45 - 14.00	Conceptualising Access In The DAA Era: Applying The Candidacy Framework To Inform Research And Practice In HCV Care For People Who Use Drugs Stine Høj, Centre de Recherche du CHUM, Canada	13.45 - 14.00	Adherence To Sofosbuvir And Velpatasvir Among People With Chronic Hcv Infection And Recent Injection Drug Use: The SIMPLIFY Study Evan Cunningham, The Kirby Institute, Australia	13.45 - 14.00	A Multi-Sectoral Model To Support Hepatitis C Testing And Treatment Access Among People Who Inject Drugs In Hanoi, Vietnam Thuy Ma Thu, Medecins Du Monde - Vietnam Mission, Vietnam
14.00 - 14.15	Hepatitis C Virus (HCV) Testing, Liver Disease Assessment And Direct-Acting Antiviral (DAA) Treatment Uptake And Outcomes In A Homeless Service In Sydney, Australia: The Liverlife Study Sahar Bajis, The Kirby Institute, University Of New South Wales, Australia	14.00 - 14.15	The Treatment As Prevention Approach Results In An Early And Marked Reduction In Prevalence Of Hepatitis C Viremia Among People With Recent Injection Drug Use. Results From The Treatment As Prevention (TRAP HEPC) Program In Iceland Valgerdur Runarsdottir, SAA Addiction Clinics, Iceland	14.00 - 14.15	Daily Dosing Of Direct Acting Antivirals (DAA) From A Public Opioid Substitution Treatment (OST) Program For Marginalised Clients In Kings Cross, Sydney Phillip Read, Kirketon Road Centre, Australia
14.15 - 14.30	Preliminary Analysis Of The Prime Study; A Randomized Controlled Trial Comparing The Hepatitis C Care Cascade In Primary Care Vs. Tertiary Care Amanda Wade, Burnet Institute, Australia	14.15 - 14.30	Engaging PWID in Community Based Treatment and Care Using a Nurse-Led, Social Network Model Sally Von Bira, The Burnet Institute, Australia	14.15 - 14.30	Indigenous Led Hepatitis C Treatment Model To Achieve Elimination In Big River First Nation Mamata Pandey, Saskatchewan Health Authority, Canada
14.30 - 14.35	Improving HCV Treatment Uptake In Prison: Breaking The 60-Day Barrier Zameer Mohamed, Imperial College London, United Kingdom	14.30 - 14.35	Real-World Data On Safety And Effectiveness Of Glecaprevir/Pibrentasvir For The Treatment Of Patients With Chronic Hepatitis C Virus Infection On Opioid Substitution Therapy: Latest Results From The German Hepatitis C-Registry Elizabeth Artwick, Medical Expressions, United States	14.30 - 14.35	Accelerating The Hepatitis C Care Cascade For Patients With Substance Use Jessica Rienstra, Lummi Tribal Health Center, United States
14.35 - 14.40	Improving Engagement With Healthcare In Hepatitis C: A Randomised Controlled Trial Of A Peer Advocacy Intervention Julian Surey, University College London, United Kingdom	14.35 - 14.40	"Lost To Follow Up" Patients Have Equivalent Sustained Viral Response Rates To Patients Attending Their Scheduled SVR12 Visit. Alison Boyle, NHS Greater Glasgow and Clyde, United Kingdom	14.35 - 14.40	The Cascade Of HCV Care Among People Who Inject Drugs In A Norwegian Low-Threshold Setting: Increasing Treatment Uptake Håvard Midgard, Oslo University Hospital, Norway
14.40 - 14.45	Care Beyond The Virus: Engaging The Most Marginalised In Hepatitis C Care Magdalena Harris, London School Of Hygiene & Tropical Medicine, United Kingdom	14.40 - 14.45	Hepatitis C Treatment In People Who Inject Drugs On Medication Assisted Therapy Versus People Attending A Needle Exchange Program NCT03093415 Andrew Seaman, Oregon Health & Sciences University, United States	14.40 - 14.45	Difficult Venous Access: Addressing This Barrier To Care In Hepatitis Treatment Clinics Sinead Sheils, Institution, Australia
14.45 - 14.50	Late Breaker Abstract Presenter, Institution, Country	14.45 - 14.50	HCV Cure Rates Among People Who Inject Drugs Not Receiving Medication Assisted Treatment in an American Indian/Alaskan Native Population Whitney Essex, Cherokee Nation Health Services, United States	14.45 - 14.50	Treatment Of Hepatitis C In A Cohort Of Former And Current Injecting Drug Users In Nairobi, Kenya Dmytro Donchuk, Médecins Sans Frontières, Belgium
14.50 - 14.55	Late Breaker Abstract Presenter, Institution, Country	14.50 - 14.55	Collocation Of Buprenorphine With HCV Treatment To Improve Adherence And Reduce Harm In PWID With HCV: Update From The ANCHOR Study Elana Rosenthal, University Of Maryland School Of Medicine, United States	14.50 - 14.55	END hepC-NM: A collaborative approach towards hepatitis C elimination in a resource scarce environment Miranda Sedillo, Echo Institute/unmhsc, United States
14.55 - 15.00	Late Breaker Abstract Presenter, Institution, Country	14.55 - 15.00	HCV Cascade of Care at an Integrated Community Facility for People who Inject Drugs Leith Morris, School Of Public Health, University Of Queensland, Australia	14.55 - 15.00	RECAP: an interprofessional comprehensive community-based care clinic for the management of hepatitis C positive and at-risk individuals in Saint John, New Brunswick, Canada Stefanie Materniak, Centre For Research, Education And Clinical Care Of At-risk Populations, Canada

15.00 - 15.30	Coffee Break & Poster Viewing		
15.30 - 17.20	Session N: Harm reduction and prevention Room: TBC Chairs: TBC	15.30 - 16.45	Session O: Challenges for enhancing HCV care among PWID in low and middle income countries Room: TBC Chairs: TBC
15.30 - 15.50	Novel HCV prevention strategies for people who inject drugs Patrizia Carrieri, Aix Marseille Université, INSERM, France	15.30 - 15.50	Together in harm reduction: Synergizing efforts between HIV and hepatitis programmes Sarah Hess, World Health Organisation, Switzerland
15.50 - 16.10	State of the art on drug treatment Julie Bruneau, Université de Montréal, Canada	15.50 - 16:10	Improving access to care for PWID in Kenya: From pilot study to national programme Abigael Lukhwaro, Médecins du Monde, Kenya
16.10 - 16.50	Supervised injecting sites, drug consumption rooms and overdose prevention: Where do we stand in 2018? Joan Colom, Public Health Agency of Catalonia, Spain Gabi Becker, Geschäftsführerin der Integrativen Drogenhilfe Frankfurt, Germany Ricardo Fuentes, City of Lisbon, Portugal Civil Society Representative	16.10 - 16.30	Successful community-led efforts to enhance HCV prevention, testing and linkage to care among PWID in low and middle-income countries Edo Agustian, Asian Network of People who Use Drugs (ANPUD)/PKNI, Asia
16.50 - 17.20	Questions & Discussion	16.30 - 16.50	The cost of diagnostics Annette Gaudino, Treatment Action Group, United States
		16.50 - 17.20	Questions & Discussion
17.20	End of Conference Day 2		
19:00 - 23:00	Conference Dinner		

Day 3	HCV treatment and access				
09.00 - 09.45	Industry Sponsored Breakfast Symposium Room: Sala I + II				
10.00 - 12.00	Session P: Management of HCV in people who inject drugs Room: Sala I + II Chairs: TBD				
10.00 - 10.20	Direct-acting antiviral therapy: Have we reached perfectovir for PWID? Brian Conway, Vancouver ID Centre, Canada				
10.20 - 10.40	Management of advanced liver disease and risk of HCC Massimo Colombo, University of Milan, Italy				
10.40 - 11.00	Life beyond SVR - It is not just about SVR: The clinical benefits of succesful DAA therapy beyond cure Alessio Aghemo, Humanitas Research Hospital, Italy				
11.00 - 11.20	Life beyond SVR - It is not just about SVR: The social benefits of succesful DAA therapy beyond cure Carla Treloar, Centre for Social Research in Health, UNSW Sydney, Australia				
11.20 - 11.30	Questions & Discussion				
11.30 - 11.45	Late Breaker Abstract Presenter, Institution, Country				
11.45 - 12.00	Late Breaker Abstract Presenter, Institution, Country				
12.00 - 12.45	Coffee Break & Poster Tour				
12.00 - 12.45	Session Q: Community Session Room: Sala I + II				
12.00 - 12.45	Panel Disussion				
12.45 - 13.45	Lunch				
13.00 - 13.45	INHSU GAM				
13.45 - 14.45	Session R: Oral Abstracts Room: Chairs: TBD	13.45 - 14.45	Session S: Late Breaker Oral Abstracts Room: Chairs: TBD	13.45 - 14.45	Session T: Oral Abstracts Room: Chairs: TBD
13.45 - 14.00	High Re-infection Rates Among People Who Inject Drugs Successfully Jasmine Schulkind, University Bristol, United Kingdom	13.45 - 14.00	Late Breaker Abstract Presenter, Institution, Country	13.45 - 14.00	Experience And Outcomes Of A High Volume Homeless Health Center-Based HCV Treatment Program In Marguerite Beiser, Boston Health Care For The Homeless, United States
14.00 - 14.15	Reinfection And Retreatment: Attitudes Among Prisoner Participants Jake Rance, Centre For Social Research In Health, Australia	14.00 - 14.15	Late Breaker Abstract Presenter, Institution, Country	14.00 - 14.15	Treating People Where They Are: Lessons From Outreach HCV Treatment For Networks Of People With Tamara Barnett, Cool Aid Community Health Centre, Canada
14.15 - 14.30	Late Breaker Abstract Presenter, Institution, Country	14.15 - 14.30	Late Breaker Abstract Presenter, Institution, Country	14.15 - 14.30	Building Bridges to Eliminate HCV in PWID: Knowledge and Planned Performance Change Among HCV Jody Gilmore, Penn Presbyterian Medical Center, United States
14.30 - 14.35	Drug Use And Reinfection During And Following Hepatitis C Virus Gregory Dore, Kirby Institute, University of New South Wales, Australia	14.30 - 14.35	Late Breaker Abstract Presenter, Institution, Country	14.30 - 14.35	Liberating Medeco-Inala From Hep C. A Study Of Micro-Elimination In Primary Care Matthew Young, Medeco-Inala, Australia
14.35 - 14.40	Low HCV Reinfection Rate After Treatment In People Who Infect Drugs (PWID) From A Prospective Cohort In Tbilisi, Georgia Niklas Luhmann, Médecins Du Monde, France	14.35 - 14.40	Late Breaker Abstract Presenter, Institution, Country	14.35 - 14.40	Chronic Hepatitis C Eradication Model Through Primary Care In British Columbia, Canada John Farley, Dr. John Farley Inc., Canada
14.40 - 14.45	Low Rate Of Reinfection Following Direct-Acting Antiviral HCV Treatment Among People With Recent Injecting Drug Use: A Real-Life Experience Håvard Midgard, Oslo University Hospital, Norway	14.40 - 14.45	Late Breaker Abstract Presenter, Institution, Country	14.40 - 14.45	Hepatitis C Care In An Opioid Substitution Treatment Unit Simon Larsson, Sahlgrenska University Hospital, Sweden
14.45 - 15.15	Coffee Break & Poster Viewing				
15.15 - 16.30	Session U: Enhancing access to HCV care for PWID Room: TBC Chairs: TBC	15.15 - 16.30	Session V: Enhancing HCV prevention and treatment in prisons Room: TBC Chairs: Niklas Luhmann and TBD		
15.15 - 15.35	Hepatitis C and inequality: how poverty, race and gender intersect with efforts to prevent, treat and eliminate? TBC	15.15 - 15.35	Needle and syringe programmes for HCV prevention in prisons: Where do we stand globally? Rick Lines, Hilary Rodham Clinton School of Law, Swansea University, United Kingdom		
15.35 - 15.55	Working towards addressing stigma TBC	15.35 - 15.55	Enhancing access to HCV testing and treatment in prisons: Lessons learned from Australia Alex Thompson, University of Melbourne, Australia		
15.55 - 16.15	Enhancing access to HCV testing and treatment among people who use drugs: Lessons from Brazil Francisco Inácio Bastos, Oswaldo Cruz Foundation, Brazil	15.55 - 16.15	Enhancing access to HCV testing and treatment in prisons: Lessons learned from Spain Joan Colom, Public Health Agency of Catalonia, Autonomous Government of Catalonia, Spain		
16.15 - 16.30	Questions & Discussion	16.15 - 16.30	Questions & Discussion		
16.30 - 17.10	Session W: Reports and Conference Closing Room: Sala I + II				
16.30 - 16.40	INHSU 2017 Conference Wrap-up				
16.40 - 16.50	Community Closing Statement				
16.50 - 17.10	Conference Closing and Introduction of Upcoming Conference				
17.10	End of Conference				